Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,082.40
(
-0.86%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
109.63
(
1.38%
)
Bitcoin
68,216.37
(
0.56%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: croumagnon post# 7556

Monday, 02/04/2008 6:41:04 PM

Monday, February 04, 2008 6:41:04 PM

Post# of 19309
I misread goseek’s question and thought he was asking about the rate of DVT in untreated patients with HD who undergo at-risk procedures.

To be clear: there should be no difference between ATryn and plasma-derived AT in efficacy at preventing DVT. This is ’s the reason the phase-3 trial was designed as a non-inferiority study.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today